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SHORT COMMUNICATION
Chlorambucil and interferon for low grade non-Hodgkin's lymphoma
A.Z.S. Rohatiner, M.A. Richards, M.J. Barnett, A.G. Stansfeld & T.A. Lister
ICRF Department ofMedical Oncology, St. Bartholomew's Hospital, London ECIA, UK.
Despite responsiveness to both chemotherapy and radiation
therapy, most patients with low grade non-Hodgkin's
lymphoma (NHL) die as a consequence of the disease.
Chlorambucil (CB) alone yields responses in approximately
seventy-five percent of patients with a median duration of
first remission of one to two years. However, although
subsequent remissions can often be achieved, the character-
istic continuous relapse pattern results in a median survival
of between five and ten years (Jones et al., 1973; Young et
al., 1977; Lister et al., 1978; Rudders et al., 1979; Hoppe et
al., 1981; Anderson et al., 1982; Gallagher et al., 1986).
It has been demonstrated that administration of leucocyte
or recombinant DNA interferon causes regression of disease
in approximately forty per cent of patients with low grade
lymphoma (Merigan et al., 1978; Louie et al., 1981; Ozer et
al., 1983; Horning et al., 1985; Wagstaff et al., 1986).
Combinations of interferon with conventional cytotoxic
agents have been investigated in murine models of leukaemia
and lymphoma (Chirigos & Peason, 1973; Gresser et al.,
1978; Slater et al., 1981; Tozawa et al., 1982; Mowshowitz et
al., 1982); longer survival was observed in animals receiving
the combination than in those receiving either drug alone.
On the basis of these observations it was decided to
investigate the concurrent administration of CB and
interferon (IFN-a2) in previously treated patients with low
grade NHL.
Twenty-three patients (median age 52 years, range 28-70)
with recurrent, low grade NHL (11 follicular, 6 centrocytic,
4 lymphoplasmacytoid, I peripheral T cell) and 1 patient
with chronic lymphocytic leukaemia received CB and IFN-ac2
as shown in Figure 1. All, except one patient with follicular
lymphoma had bone marrow infiltration at the time of
treatment.
Treatment protocol
6 weeks 2 weeks
CB: 10mg daily [ |III L
2 weeks 2 weeks
IFN-x2:2x106Um-2
daily 3x weekly; s.c.
Figure 1
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Toxicity Eleven patients completed therapy at full doses
with no treatment delay. The reasons for stopping treatment
in the remainder were disease progression (5), myelo-
suppression (5), death due to septicaemia (1) and interferon
intolerance (1). Myelosuppression also precluded continu-
ation of CB in two patients at 6 and 12 weeks respectively.
The flu-like symptoms experienced by most patients were
similar to those previously described with interferon alone
(Merigan et al., 1977; Priestman, 1980; Horning et al., 1982;
Sherwin et al., 1982). The haematological toxicity was that
to be expected in such a patient population treated with CB
alone (Table I).







Erythema at injection site 1
Platelets <20x 109 1-l 2a
Platelets <50 x 1091-1 and
Neutrophils <0.5 x 109 1-l 3a
Neutrophils < 1.0 x 1091- 1 2b
aTreatment stopped due to myelosuppression;
bChlorambucil stopped, IFN-o; continued.
Response Responses were observed in 14 out of 23 patients
overall (1 CR, 13 PR) including 8 out of 11 patients with
follicular lymphoma (1 CR, 7 PR). In 4 patients, the combi-
nation resulted in a greater degree of clinical response than
had previously been observed with CB alone.
This study has demonstrated that it is possible to
administer CB and IFN-o2 on the schedule described to the
majority of patients with follicular lymphoma and achieve
responses, even if not CR, in approximately three quarters.
This is encouraging considering the amount of prior therapy
received. A randomised study is currently in progress in
previously untreated patients with advanced follicular
lymphoma to compare the combination with CB alone.
We are indebted to the medical and nursing staff of Annie Zunz and
Dalziel wards, to Dr J. Amess, Department of Haematology and to
Jane Ashby for preparing the manuscript. IFN-a2 was supplied by
Schering-Plough.
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